Back to Search
Start Over
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
- Source :
-
Frontiers in oncology [Front Oncol] 2021 Sep 16; Vol. 11, pp. 737645. Date of Electronic Publication: 2021 Sep 16 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Up to 60% of patients with aggressive B-cell lymphoma who receive chimeric antigen receptor (CAR) T-cell therapy experience treatment failure and subsequently have a poor prognosis. Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains a potentially curative approach for patients in this situation. Induction of a deep response prior to alloHSCT is crucial for long-term outcomes, but the optimal bridging strategy following relapse after CAR T-cell therapy has not yet been established. Polatuzumab vedotin, an antibody drug conjugate targeting CD79b, is a novel treatment option for use in combination with rituximab and bendamustine (Pola-BR) in relapsed or refractory disease. Patients: We report two heavily pretreated patients with primary refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma (PMBCL) respectively who relapsed after therapy with CAR T-cells with both nodal and extranodal manifestations of the disease. After application of three courses of Pola-BR both patients achieved a complete metabolic remission. Both patients underwent alloHSCT from a human leukocyte antigen (HLA)-mismatched donor following conditioning with busulfan and fludarabine and are disease free 362 days and 195 days after alloHSCT respectively. We conclude that Pola-BR can be an effective bridging therapy before alloHSCT of patients relapsing after CAR T-cell therapy. Further studies will be necessary to define the depth and durability of remission of this salvage regimen before alloHSCT.<br />Competing Interests: G-NF, UP, and VV received Honoraria from Novartis and Gilead. MJ and SS received Honoraria from Novartis. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2021 Gerhardt, Jentzsch, Georgi, Sretenović, Cross, Bach, Monecke, Leiblein, Hoffmann, Todorović, Bila, Sabri, Schwind, Franke, Platzbecker and Vučinić.)
Details
- Language :
- English
- ISSN :
- 2234-943X
- Volume :
- 11
- Database :
- MEDLINE
- Journal :
- Frontiers in oncology
- Publication Type :
- Report
- Accession number :
- 34604075
- Full Text :
- https://doi.org/10.3389/fonc.2021.737645